Catalyst Wire Dossier Catalyst Wire Dossier

BI 6727 (volasertib)

volasertib · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 6727 (volasertib), covering 2023-10-03 to 2023-10-03. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia [Phase 2]

See pricing